NGVB Logo


Report Summary

Lineage-specific BCL11A knockdown circumvents toxicities and reverses sickle phenotype


Study Summary

Overall Study Design 
Here we present preclinical data using an innovative gene therapy approach for the treatment of SCD 
More details on this study are available to registered users. To get access, you need to:
  1. Have an NGVB account: click here to create one
  2. Send an e-mail to the NGVB Manager to request access:

    NGVB Manager
    317-274-4519
    Please enable JavaScript in your browser to see the e-mail address.